Home / Pharmaceutical company intelligence
Nabiqasim Industries (Pvt) Ltd., logo
Pharmaceutical company intelligence

Nabiqasim Industries (Pvt) Ltd.,

Private pharmaceutical manufacturer · Karachi · Pakistan

Pakistan-based pharmaceutical manufacturer producing branded generic formulations with domestic and international operations.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗ LinkedIn ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation23 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date4 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Legal / official name
Nabiqasim Industries (Pvt.) Ltd.
Company type
Private pharmaceutical manufacturer
Address
5th Floor, Commerce Centre, Hasrat Mohani Road, Karachi, Pakistan
Phone
+92 21 111 742 762
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
100%
DRAP manufacturing licenceAs published by the DRAP Licensing Division. DRAP issues this list for stakeholder review and states it is not a reference for litigation, claims or citation.
Formulation 000105 Nabi Qasim Industries (Pvt) Ltd. · Sindh
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000105 368 linked products · source seen 23 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx365public portfolio records represented
REG272unique registrations represented
IDX39indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR365current validated price records
G118generic molecules in indexed catalogue
DF15dosage-form groups
TA16therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage100%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage99%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixNabiqasim Industries (Pvt) Ltd.,Share of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nabiqasim-industries-pvt-ltdGenerated 24 Sep 2026Anti-infectives135 · 37%CNS & mental health55 · 15%Cardiovascular51 · 14%Endocrine & metabolic40 · 11%Hematology & thrombosis20 · 5%Gastrointestinal & hepatology20 · 5%Respiratory & allergy10 · 3%Other therapeutic areas34 · 9%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioNabiqasim Industries (Pvt) Ltd.,Distribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nabiqasim-industries-pvt-ltdGenerated 24 Sep 2026365presentationsTablet224 · 61%Injection40 · 11%Capsule29 · 8%Suspension19 · 5%Cream17 · 5%Sachet9 · 2%Other forms27 · 7%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionNabiqasim Industries (Pvt) Ltd.,Current company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nabiqasim-industries-pvt-ltdGenerated 24 Sep 2026335comparable productsBelow peer median63 · 19%Near peer median112 · 33%Above peer median160 · 48%Company median price position+4.4%Lowest-price equivalents33Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsNabiqasim Industries (Pvt) Ltd.,Companies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/nabiqasim-industries-pvt-ltdGenerated 24 Sep 2026Bio-Labs(Pvt) Ltd53 shared45% overlapAtco Laboratories Limited50 shared42% overlapM/s. Genix Pharma (Pvt) Ltd.49 shared42% overlapCCL Pharmaceuticals (Pvt.) Limited49 shared42% overlapMacter International Limited48 shared41% overlapMediate Pharmaceutical Pvt Ltd48 shared41% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives135 products · 37%
CNS & mental health55 products · 15%
Cardiovascular51 products · 14%
Endocrine & metabolic40 products · 11%
Hematology & thrombosis20 products · 5%
Gastrointestinal & hepatology20 products · 5%
Respiratory & allergy10 products · 3%
Vitamins, minerals & nutrition9 products · 2%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antidiabetic medicines39 products · 11%
Antifungals32 products · 9%
Antivirals29 products · 8%
Antipsychotics29 products · 8%
Lipid-lowering medicines16 products · 4%
Macrolide antibacterials16 products · 4%
Third-generation cephalosporins13 products · 4%
Antiepileptics13 products · 4%
Formulation footprint

Dosage forms

Tablet224 products
Injection40 products
Capsule29 products
Suspension19 products
Cream17 products
Sachet9 products
Syrup8 products
Gel5 products
Ointment4 products
Solution3 products
Infusion2 products
Pessary2 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 Glempa-MEmpagliflozin + Metformin 12presentations 12.5 mg + 1000 mg, 12.5 mg + 500 mg, 12.5 mg + 850 mg, 5 mg + 1000 mg · Tablet #2 Am-DescolAmlodipine + Atorvastatin 10presentations 10 mg + 10 mg, 10 mg + 20 mg, 10 mg + 40 mg, 5 mg + 10 mg · Tablet #3 NixvomOndansetron 9presentations 4 mg, 4 mg/2 mL, 8 mg, 8 mg/4 mL · Tablet, Injection #4 XarivaRivaroxaban 9presentations 10 mg, 15 mg, 2.5 mg, 20 mg · Tablet #5 ClarithroClarithromycin 8presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Tablet, Injection #6 HypovirAciclovir 8presentations 200 mg, 200 MG/5 mL, 250 mg, 400 mg · Tablet, Suspension, Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median6319% of comparable products
Near market median112within ±5% of median
Above market median16048% of comparable products
Lowest-price equivalents33ties included
Company median price position +4.4% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Predsol Oph. Susp 10 mg/mLPrednisolone · Suspension · 15ml PKR 5.42/mL-79.8% vs market median Silderm 10 mg/gSilver sulfadiazine · Cream · 250g PKR 1.94/g-62.5% vs market median Normitab-25 25 mgAtenolol · Tablet · 14's PKR 3.65/tablet-35.2% vs market median Livent 1 mgEntecavir · Tablet · 30s PKR 386.65/tablet-34.8% vs market median Livent 0.5 mgEntecavir · Tablet · 30s PKR 232.01/tablet-34.8% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Bio-Labs(Pvt) Ltd236 products · 82 generics 53shared generics Atco Laboratories Limited278 products · 94 generics 50shared generics M/s. Genix Pharma (Pvt) Ltd.297 products · 97 generics 49shared generics CCL Pharmaceuticals (Pvt.) Limited249 products · 99 generics 49shared generics Macter International Limited256 products · 93 generics 48shared generics Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 48shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers272Distinct registrations among indexed, published, presentation-validated products only
Verified price observations368
Products with a verified price365
Products with multiple price observations3
Source records with multiple versions361
Latest portfolio source check22 Sep 2026
Latest effective price date4 Aug 2026
Latest source observation23 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

272 unique registration(s) · 39 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Intelligence filter: Drug classAntidiabetic medicines Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Dapxi Dapagliflozin 10 mg Tablet 14's 110209 PKR 883.89 PKR 63.14/tablet 8% below median
Dapxi Dapagliflozin 10 mg Tablet 10s 110209 PKR 662.54 PKR 66.25/tablet Near median
Dapxi Dapagliflozin 5 mg Tablet 14's 110382 PKR 836.77 PKR 59.77/tablet 8% below median
Dapxi Dapagliflozin 5 mg Tablet 10s 110382 PKR 597.70 PKR 59.77/tablet 8% below median
Dapxi Met Dapagliflozin + Metformin 5 mg + 1000 mg Tablet 56s 110208 PKR 3,194.46 PKR 57.04/tablet Near median
Dapxi Met Dapagliflozin + Metformin 5 mg + 1000 mg Tablet 28s 110208 PKR 1,630.21 PKR 58.22/tablet Near median
Dapxi Met Dapagliflozin + Metformin 5 mg + 850 mg Tablet 56s 110381 PKR 3,189.07 PKR 56.95/tablet Near median
Dapxi Met Dapagliflozin + Metformin 5 mg + 850 mg Tablet 28s 110381 PKR 1,627.52 PKR 58.13/tablet Near median
Dapxi Met + Dapagliflozin + Metformin 5 mg + 1000 mg Tablet 14s 110208 PKR 831.93 PKR 59.42/tablet Near median
Dapxi Met + Dapagliflozin + Metformin 5 mg + 850 mg Tablet 14s 110381 PKR 830.59 PKR 59.33/tablet Near median
Dapxi-Met XR Dapagliflozin + Metformin 5 mg + 500 mg Tablet 14's 120012 PKR 1,021.74 PKR 72.98/tablet No comparator
Dapxi-Met XR Dapagliflozin 5 mg Tablet 28's 120012 PKR 2,003.10 PKR 71.54/tablet 10% above median
DIAMET Metformin 250 mg Tablet 50's 055585 PKR 116.99 PKR 2.34/tablet Near median
Diamet Metformin 250 mg Tablet 30's 055585 PKR 70.19 PKR 2.34/tablet Near median
DIAMET Metformin 500 mg Tablet 50's 055586 PKR 164.15 PKR 3.28/tablet 22% above median
Glempa Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 14s 110224 PKR 665.37 PKR 47.53/tablet 21% below median
Glempa Empagliflozin 10 mg Tablet 30 110225 PKR 1,928.28 PKR 64.28/tablet 22% below median
Glempa Empagliflozin 10 mg Tablet 14s 110225 PKR 918.24 PKR 65.59/tablet 21% below median
Glempa Empagliflozin 25 mg Tablet 30 110226 PKR 2,308.01 PKR 76.93/tablet 23% below median
Glempa Empagliflozin 25 mg Tablet 14s 110226 PKR 1,099.06 PKR 78.50/tablet 22% below median
Glempa-M Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 14s 110224 PKR 665.37 PKR 47.53/tablet 21% below median
Glempa-M Empagliflozin + Metformin 5 mg + 1000 mg Tablet 14s 110374 PKR 562.24 PKR 40.16/tablet 22% below median
Glempa-M Empagliflozin + Metformin 12.5 mg + 500 mg Tablet 28s 110375 PKR 1,281.29 PKR 45.76/tablet 17% below median
Glempa-M Empagliflozin + Metformin 12.5 mg + 500 mg Tablet 14s 110375 PKR 654.07 PKR 46.72/tablet 15% below median
Glempa-M Empagliflozin + Metformin 5 mg + 850 mg Tablet 14s 110376 PKR 560.83 PKR 40.06/tablet 21% below median
Glempa-M Empagliflozin + Metformin 5 mg + 850 mg Tablet 10s 110376 PKR 399.79 PKR 39.98/tablet 21% below median
Glempa-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 30s 110377 PKR 1,392.89 PKR 46.43/tablet Near median
Glempa-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 10s 110377 PKR 473.24 PKR 47.32/tablet Near median
Glempa-M Empagliflozin + Metformin 12.5 mg + 850 mg Tablet 14s 110377 PKR 663.95 PKR 47.43/tablet Near median
Glempa-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 30s 110378 PKR 1,421.15 PKR 47.37/tablet Near median
Glempa-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 10s 110378 PKR 483.13 PKR 48.31/tablet Near median
Glempa-M Empagliflozin + Metformin 5 mg + 500 mg Tablet 14s 110378 PKR 676.67 PKR 48.33/tablet Near median
Glempa-MXR Empagliflozin + Metformin 5 mg + 1000 mg Tablet 14's 118000 PKR 788.41 PKR 56.32/tablet 10% above median
Glempa-MXR Empagliflozin + Metformin 5 mg + 1000 mg Tablet 14's 118001 PKR 931.32 PKR 66.52/tablet 30% above median
Glempa-MXR Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 14's 118002 PKR 932.93 PKR 66.64/tablet 12% above median
Glempa-MXR Empagliflozin + Metformin 12.5 mg + 1000 mg Tablet 14's 118003 PKR 945.77 PKR 67.56/tablet 13% above median
Glicotron Gliclazide 80 mg Tablet 20's 025911 PKR 256.66 PKR 12.83/tablet 23% above median
Glicotron Gliclazide 30 mg Tablet 30's 127903 PKR 434.16 PKR 14.47/tablet 8% above median
Glicotron Gliclazide 60 mg Tablet 30's 127904 PKR 720.07 PKR 24.00/tablet 5% below median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). Nabiqasim Industries (Pvt) Ltd — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 24, 2026, from https://medinfobase.com/company/nabiqasim-industries-pvt-ltd/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.